NOV 30, 2021 11:00 AM PST

Terpene-Mediated Modulation of Cannabinoid Activity

WRITTEN BY: Nadine Husami

A popular theory – the “entourage effect” – has been gaining traction amongst the cannabis sciences community in recent years.

The entourage effect is a hypothesized phenomenon in which different combinations of phytocannabinoids (such as Δ9-tetrahydrocannabinol, THC; and cannabidiol, CBD) and terpenes (such as β-caryophyllene and β-myrcene) interact to generate unique, synergistic effects that are distinct from the effect of either compound alone.

However, experimental evidence supporting the entourage effect has been relatively limited within the field thus far. Notably, the in vivo physiological effects of these proposed interactions in both therapeutic and recreational contexts remains vastly understudied.

Of the two phytochemical families, cannabinoids have received more attention in functional and medical research investigations. Terpenes, on the other hand, have yet to be studied so extensively.

Accordingly, there has been a lack of research able to confirm a role for terpenes in modulating cannabinoid activity. Moreover, it remains uncertain as to whether individual terpenes can influence cannabinoid activity directly (via interaction with cannabinoid 1/2 receptors, CB1/2R) or indirectly.

So, do terpenes actually play a role in modulating cannabinoid activity?

Recent research suggests yes! But how do they do it?

Just months ago, researchers from a study published in Nature’s Scientific Reports were the first to demonstrate that terpenes interact with cannabinoids directly to generate an additive effect that enhances cannabinoid activity.

Using a combination of in vitro techniques and in vivo mouse model experiments, the study sought to interrogate the functional and modulatory effects of several predominant Cannabis sativa terpenes both individually and when combined with a known cannabinoid agonist.

The terpenes investigated in this study include α-humulene, geraniol, linalool, and β-pinene, which were selected based on their measured concentrations in C. sativa (with α-humulene, linalool, and β-pinene found at increased concentrations and geraniol found at a minimal concentration).

Experimental analyses of individual terpene interactions demonstrated that these terpenes can selectively modulate the activity of a synthetic cannabinoid (the canonical cannabinoid agonist, WIN55,212), implicating a role for terpenes in modulating biological phytocannabinoids.

Further in vitro experiments revealed that these specific terpenes targeted both cannabinoid and non-cannabinoid receptors, during which all terpenes were shown to activate CB1R, and some were also shown to activate additional receptors. This study is the first to identify CB1 and A2a as target terpene receptors.

These results indicate that not only are terpenes cannabimimetic – they are poly-pharmacological agents, too!

Although further functional studies will need to be conducted using biological phytocannabinoids to validate these findings, this study paves the way for a whole new realm in precision therapeutics. If further research is able to validate and hone in on which synergistic effects are produced by distinct phytochemical combinations, terpenes hold the potential to improve therapeutic efficacy by modulating cannabinoid activities: desired cannabinoid effects (such as the analgesic effects characteristic of CBD) could be enhanced, whereas unwanted side effects (psychoactive ‘high’ from THC) could be reduced.

 

Sources: Labroots; Nature’s Scientific Reports; Glosbe Dictionary

About the Author
  • Nadine (She/Her) is a Cannabis Sciences category writer at Labroots. She received her BSc in Biotechnology from Niagara University, where she investigated the use of bacterial glycoside hydrolases for the production of universal blood via hydrolytic ABO antigen cleavage. She also performed cannabis research during her undergraduate career as a laboratory associate for a plant genetics biotechnology company. She is currently a Biochemistry PhD in training at the University at Buffalo; her current thesis work investigates the role of long noncoding RNAs in ocular pathologies.
You May Also Like
JUL 01, 2021
Health & Medicine
Cannabis Can Ease Symptoms in Women WIth Gynecological Cancers
JUL 01, 2021
Cannabis Can Ease Symptoms in Women WIth Gynecological Cancers
A small study has shown that cannabis can help reduce unpleasant symptoms in women with gynecological cancers. The five ...
JUL 27, 2021
Health & Medicine
Marijuana Use Does Not Encourage Extra Cigarette Smoking: Study
JUL 27, 2021
Marijuana Use Does Not Encourage Extra Cigarette Smoking: Study
Recreational marijuana is now legal in 19 states, as well as in Washington, D.C., and Guam. But has this loosening of ca ...
AUG 05, 2021
Cannabis Sciences
Brain's Version of THC Reduces Seizures, Increases Side Effects
AUG 05, 2021
Brain's Version of THC Reduces Seizures, Increases Side Effects
An endocannabinoid similar to tetrahydrocannabinol (THC) that naturally occurs in the brain reduces seizure activity. Ho ...
SEP 09, 2021
Clinical & Molecular DX
A Drug Test for Synthetic Cannabis Use
SEP 09, 2021
A Drug Test for Synthetic Cannabis Use
Designer drugs are synthetic analogs of prohibited substances such as cocaine and LSD made in clandestine laboratories a ...
OCT 22, 2021
Cannabis Sciences
Cannabinoid Pain Treatment for Kidney Disease Patients
OCT 22, 2021
Cannabinoid Pain Treatment for Kidney Disease Patients
According to a recent review of cannabis in kidney disease symptom management conducted by University of British Columbi ...
NOV 08, 2021
Drug Discovery & Development
A case study of CBD's tumor shrinking potential
NOV 08, 2021
A case study of CBD's tumor shrinking potential
A recent article published in the British Medical Journal reported the case of a woman who shrank a tumor by taking CBD. ...
Loading Comments...